The most significant finding of this study is that the simplified herbal agent HBX-6 has a strong therapeutic potential in the suppression of BPH via the inhibition of the E2F1 pathway in a testosterone-induced BPH mouse model. Here, E2F1 is linked to benign prostatic hyperplasia.